Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BD’s TriPath Imaging Buyout Would Integrate Cancer Diagnostics Partner

This article was originally published in The Gray Sheet

Executive Summary

Becton Dickinson will gain TriPath Imaging's SurePath liquid-based Pap test and fledgling molecular oncology diagnostics business should its $350 mil. acquisition offer be accepted

You may also be interested in...



BD Diagnostics Revenue Up 3% In Fiscal First Quarter, But Medical Sales Fall

BD's diagnostics revenue rose 3.3% to $540.1 million in the firm's fiscal first quarter, aided by sales of safety-engineered products, cancer tests and infectious disease assays, the firm reported Jan. 28

BD Diagnostics Revenue Up 3% In Fiscal First Quarter, But Medical Sales Fall

BD's diagnostics revenue rose 3.3% to $540.1 million in the firm's fiscal first quarter, aided by sales of safety-engineered products, cancer tests and infectious disease assays, the firm reported Jan. 28

Earnings Calls In Brief

Consumers still spending for Allergan aesthetic treatments: Aesthetic product sales pushed Allergan's device revenues ahead 70% in the fourth quarter compared to a year ago, to $216.9 million, or 49% on a pro-forma local currency basis after accounting for acquisitions, the firm reports Jan. 30. Sales of facial dermal fillers, including Juvederm, more than doubled to $61 million while breast implant sales increased 38% to $81 million and sales of obesity intervention products, including the Lap-Band system, ballooned 50% to $74 million. Overall, the diversified device and drug maker reported fourth quarter sales of $1.07 billion, up 31.7% from the same quarter a year ago. "While we obviously cannot fully predict future economic trends and their impact on our markets, up to today we have not detected any impact on our sales of any slowdown in consumer spending in the United States or other major markets in the world," CEO David Pyott noted. For 2008, the company forecasts device sales of $870 million-$955 million, up 12%-23% from $774 million in 2007, including facial aesthetics sales of $225 million-$255 million; breast implant sales of $330 million-$350 million; and obesity intervention sales of $315 million-$350 million

Related Content

UsernamePublicRestriction

Register

MT023889

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel